You are here
Pharmareview Corporation
UEI: D9MKKSEF5EC1
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Lactoferrin Modulation of Granuloma Pathology
Amount: $1,696,381.00ABSTRACT Host immunity plays a major role in development of Tuberculosis diseaseTuberculosis infected individuals respond by formation of granulomaswhich contain bacilliHoweverorganisms within granulo ...
STTRPhase II2017Department of Health and Human Services National Institutes of Health -
Optimized lactoferrin for treatment of intracerebral hemorrhage
Amount: $1,604,091.00DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with the highest mortality rate of all stroke subtypes ICH is one of the leading causes of long te ...
STTRPhase II2016Department of Health and Human Services National Institutes of Health -
Lactoferrin Modulation of Granuloma Pathology
Amount: $224,725.00DESCRIPTION provided by applicant Host immunity plays a major role in development of Tuberculosis disease Tuberculosis infected individuals respond by formation of granulomas which contain bacil ...
STTRPhase I2015Department of Health and Human Services National Institutes of Health -
Optimized lactoferrin for treatment of intracerebral hemorrhage
Amount: $824,223.00DESCRIPTION provided by applicant Intracerebral hemorrhage ICH is a major public health problem with highest mortality rate of all stroke subtypes and long term disability Since there are no ava ...
STTRPhase I2014Department of Health and Human Services National Institutes of Health -
Lactoferrin for Immunomodulation of Systemic Inflammatory Response Syndrome
Amount: $1,424,350.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop a biologic therapeutic to treat systemic inflammatory response syndrome (SIRS) using a novel human recombinant lacto ...
STTRPhase II2010Department of Health and Human Services National Institutes of Health -
Lactoferrin for Immunomodulation of Systemic Inflammatory Response Syndrome
Amount: $203,739.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop a biologic therapeutic to treat systemic inflammatory response syndrome (SIRS) using a novel human recombinant lact ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health -
Lactoferrin as an Adjuvant for Cellular Immunity
Amount: $2,977,920.00The Specific Aims of the proposal will be modified to reflect a change in scope, according to recommendations from the review panel. Specifically, the revised scope of the project will now only includ ...
STTRPhase II2005Department of Health and Human Services National Institutes of Health -
Lactoferrin as an Adjuvant for Cellular Immunity
Amount: $1,109,580.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop human recombinant Lactoferrin as an adjuvant to BCG to augment cell mediated immunity (CMI) and protect alveolar i ...
SBIRPhase II2005Department of Health and Human Services National Institutes of Health -
LACTOFERRIN AS AN ADJUVANT FOR CELLULAR IMMUNITY
Amount: $99,965.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop bovine and human Lactoferrins as an adjuvant to augment antibody and cell mediated immunity. We will specifically ...
STTRPhase I2002Department of Health and Human Services National Institutes of Health
